Company Overview

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on the development and commercialization of differentiated anti-infective therapies addressing drug-resistant bacterial pathogens. The company operates within the biopharmaceutical and infectious disease industries, with a primary emphasis on treatments for urinary tract infections (UTIs) caused by multi-drug resistant organisms. Its core value proposition centers on advancing novel beta-lactam antibiotics designed to overcome resistance mechanisms that limit the effectiveness of existing therapies.

The company’s primary product is ORLYNVAH™ (sulopenem etzadroxil/probenecid), an oral antibiotic approved in the U.S. for the treatment of uncomplicated UTIs. Iterum’s unique positioning lies in its focus on oral and IV formulations of the same antibiotic, enabling step-down therapy and continuity of care. Iterum Therapeutics plc was founded in 2015 through the spin-out of anti-infective assets from AstraZeneca plc, and it completed its initial public offering in 2018, establishing itself as a standalone public company dedicated to infectious disease innovation.

Business Operations

Iterum generates value primarily through the development and commercialization of ORLYNVAH™, as well as through potential licensing and collaboration arrangements. The company historically operated as a single reporting segment focused on anti-infective research and development, with activities spanning clinical development, regulatory engagement, manufacturing oversight, and commercial preparation. Revenue generation has been limited and primarily related to milestone payments and early commercial activities following regulatory approval.

Operations are conducted through Iterum Therapeutics International Limited and other wholly owned subsidiaries, with research, regulatory, and corporate functions distributed across Ireland and the United States. The company controls the global rights to sulopenem, with the exception of certain territories licensed to partners. Iterum has entered into strategic regional licensing agreements, including a partnership with Menarini Group covering commercialization outside the United States, supporting international reach while conserving internal resources.

Strategic Position & Investments

Iterum’s strategic direction is centered on the successful U.S. launch and broader global commercialization of ORLYNVAH™, as well as lifecycle management opportunities for sulopenem in additional indications. The company has prioritized capital-efficient execution, focusing investment on regulatory approval, market access, and post-marketing commitments rather than broad pipeline expansion. Growth initiatives include leveraging existing clinical data to support ex-U.S. approvals through partners and exploring institutional use of IV sulopenem.

Major investments have largely been directed toward clinical trials, regulatory submissions, and manufacturing readiness. The approval of ORLYNVAH™ in 2024 represents a significant strategic milestone, transitioning Iterum from a development-stage company toward commercial operations. Beyond sulopenem, public disclosures indicate limited near-term pipeline diversification; data inconclusive based on available public sources regarding additional advanced-stage assets or acquisitions.

Geographic Footprint

Iterum Therapeutics plc is headquartered in Dublin, Ireland, and maintains a significant operational presence in the United States, particularly for regulatory, clinical, and commercial activities. The company’s geographic footprint reflects its dual focus on U.S. regulatory approval and international partnering, with investments and oversight spanning North America and Europe.

Through licensing agreements, Iterum has extended its potential market presence into additional regions, including parts of Europe, Asia, and other international markets managed by partners. While direct commercial infrastructure outside the U.S. remains limited, the company’s global rights structure and partnerships provide international reach without substantial fixed operational expansion.

Leadership & Governance

Iterum is led by an executive team with extensive experience in pharmaceuticals, anti-infective development, and public company governance. Leadership emphasizes disciplined capital allocation, regulatory execution, and addressing unmet medical needs in infectious diseases. The board and management have articulated a strategy focused on delivering clinically meaningful therapies while navigating the challenging economics of antibiotic development.

Key executives include:

• Corey N. Fishman – Chief Executive Officer
• Barry Shine – Chief Financial Officer
• Paul Stone – Chief Medical Officer
• Patrick McKenna – Chief Operating Officer

The leadership team’s strategic vision centers on responsible commercialization of ORLYNVAH™, maximizing shareholder value through partnerships, and contributing to global efforts against antimicrobial resistance.